BCYC — Q2 2026 Financial Report Analysis

Bicycle Therapeutics, a UK-based cancer drug developer with no approved products, cut its second-quarter 2026 net loss by 36% to $50.3 million, or $0.72 per share (each US-listed ADS represents one ordinary share). The improvement came almost entirely from spending less: research and development (R&D) costs fell 42% to $41.2 million after the company stopped pushing its most advanced drug, zelenectide pevedotin, toward approval on its own and cut about 30% of its staff in March. Revenue, which comes only from partnership payments, shrank to $0.6 million as two big-pharma collaborations ended. With $510.1 million in cash, Bicycle now says its money lasts into 2030.

At a glance

• $41.2 million R&D spend (-42%): most of the drop ($24.8 million) is lower zelenectide trial costs, so this is a smaller company by choice, not a more efficient one.
• $510.1 million cash, down $118.1 million in six months: first-half operating cash outflow was $115.5 million, but management expects the March cuts to roughly halve annual operating expenses, which is what supports the "into 2030" runway claim.
• $0.6 million collaboration revenue (-78%): partnerships with Genentech (ended August 2025) and Novartis (ended February 2026) no longer contribute, removing a source of outside funding and outside validation.

The numbers

Operating margin is not shown: with revenue of $0.6 million against $55.2 million of expenses, the ratio carries no useful information.

What changed: from zelenectide to nuzefatide

Bicycle's technology makes "bicyclic peptides", small, ring-shaped protein fragments designed to latch onto a target on cancer cells and deliver a toxic payload (a "Bicycle Drug Conjugate") or a radioactive one (a "Bicycle Radioconjugate"). Their pitch versus antibody-based drugs is a better balance of effectiveness and side effects.

Until early 2026 the lead program was zelenectide pevedotin, aimed at Nectin-4 in bladder cancer (metastatic urothelial cancer). In March the company changed course. The 10-Q says that although the Duravelo-2 dose-selection data were "promising," with response rates "comparable to published rates for existing standards of care," Bicycle converted the trial from a registrational Phase 2/3 to a randomized Phase 2 and "deprioritized the program for internal development while we evaluate next steps... following preliminary feedback from regulatory agencies." Its breast and lung cancer trials of zelenectide are being discontinued. In plain terms: matching the existing standard of care was likely not enough to win approval against an entrenched competitor, so the company stopped funding the expensive late-stage trial.

Focus has moved to nuzefatide pevedotin, which targets EphA2, a protein that antibody drugs have struggled to hit. The first patient in a Phase 2 trial in recurrent pancreatic cancer was dosed in April 2026. Early bladder-cancer data presented at AACR covered just 14 patients. A first company-run trial of a radioconjugate, BT1702, is planned for 2027.

What the headline numbers hide

• The smaller loss is mostly fewer trials. Of the $29.9 million R&D decline, $24.8 million is lower zelenectide spending because the dose-selection portion of Duravelo-2 was fully enrolled; $5.6 million and $1.5 million came from lower staff costs and share-based pay. Partly offsetting this, UK R&D tax credits (cash rebates from the UK government, booked as a reduction of R&D expense) were $5.0 million lower because there was less qualifying spending.
• Restructuring costs are in the numbers, not stripped out. Bicycle reports no adjusted figures. Severance for the March layoffs cost $1.3 million in Q2 and $5.5 million in the first half, out of about $6.5 million expected in total.
• Cash burn is slightly above the reported loss. First-half operating cash outflow was $115.5 million against a $111.2 million net loss, a normal gap for a company paying out severance and waiting on tax-credit refunds.
• Interest income is falling with the cash pile. Interest and other income dropped 42% to $4.4 million as cash balances declined; this cushion will keep shrinking.
• No dilution in the quarter. Weighted shares were 69.8 million versus 69.3 million a year ago, so the per-share improvement matches the improvement in the loss itself.

Takeaway: Bicycle traded its nearest shot at an approved drug for a longer runway. Cutting zelenectide and 30% of staff turned a $79 million quarterly loss into $50 million and stretched cash into 2030, but the company now depends on earlier-stage programs (nuzefatide in Phase 2, radioconjugates not yet in the clinic) with no partner revenue behind them.

Outlook

Management guides only on cash: $510.1 million is expected to fund operations into 2030, based on the March reprioritization cutting annual operating expenses by about 50%. It also expects R&D and G&A expenses to "decrease in the near term." Pipeline milestones named in the release are continued enrolment in the nuzefatide pancreatic cancer Phase 2 and the start of the BT1702 Phase 1 trial in 2027.

Our view: the second half should show the full effect of the layoffs, with the remaining ~$1 million of severance and quarterly losses likely settling below Q2's $50.3 million. The near-term catalysts are a decision on zelenectide (a partnership or out-license would bring cash and validation; quietly shelving it would not) and the first efficacy data from nuzefatide in pancreatic cancer, a disease where few drugs work. Until one of those lands, Bicycle's value rests on its cash and its platform rather than on any single drug.

Source: Bicycle Therapeutics Q2 2026 earnings release (Exhibit 99.1 to Form 8-K, filed July 30, 2026) and Form 10-Q for the quarter ended June 30, 2026.